Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Good News! 1 dose of Regeneron antibody cocktail can cut the risk of COVID-19 for up to 8 months

Indo-Asian News Services
Updated: November 9th, 2021, 14:10 IST
in Coronavirus, Feature, National
0
Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

Regeneron Pharmaceuticals Inc.’s antibody cocktail cut the risk of contracting Covid-19 by 82% for up to eight months, according to a company-sponsored study that could pave the way for its broader use.

The monoclonal antibody cocktail, known as REGEN-COV, is available under an emergency use authorization in the U.S. to treat outpatients at risk of developing severe symptoms. It’s also allowed as a preventive therapy for certain people who aren’t fully vaccinated or who are immunocompromised, and have known or likely exposure to the virus.

Also Read

Nine killed-Rajasthan

Nine killed as pilgrims’ vehicle rams into parked truck in Rajasthan’s Kota

16 minutes ago
Nepal PM Balendra Shah

Nepal PM Balendra Shah to hold talks with Modi November 23 during two-day state visit

21 minutes ago

The company has asked the US Food and Drug Administration to expand the authorization so the drug can be used to prevent infections, even when it’s given before a person has been exposed.

“These data add to the increasing body of evidence supporting use of REGEN-COV to prevent Covid-19 in uninfected individuals, which may be especially useful for the many immunocompromised people who do not respond adequately to vaccines and remain ‘prisoners of the pandemic,’” George Yancopoulos, president and chief scientific officer at Regeneron, said in a statement.

The field for Covid treatments is growing more crowded, with Merck & Co. and Pfizer Inc. developing pills that have shown promising results in patients early in the course of disease. While monoclonal antibodies like Regeneron’s were developed earlier in the pandemic and may be used before the virus takes hold, the pills — if authorized — would be more convenient to transport and administer.

Analysts earlier in the year questioned the long-term prospects of Covid-19 treatments as vaccination rates increased and the number of new infections slowed. Regeneron, along with other drugmakers that produce monoclonal antibodies that jump start the immune system’s fight against the virus, have pitched the preventive use of their drugs.

The approach could particularly benefit people with weakened immune systems who may not develop sufficient protection after vaccination and are at higher risk of breakthrough infections, thereby fueling long-term demand.

The late-stage study, jointly run with the National Institute of Allergy and Infectious Diseases, enrolled people who lived in a household with someone diagnosed with Covid within the previous four days. Earlier results from the trial showed the drug cut the risk of infection by 81% within the first month. The new data shows the protection was maintained, with an 82% reduction in symptomatic infections for as long as eight months after the therapy was administered.

During the study, none of the people in the treatment group were hospitalized due to Covid, compared with six people in the placebo group. No deaths stemming from Covid infection occurred in either group.

Participants were allowed to get vaccinated after the first month. Immunization rates were balanced between those given placebo and those given the actual treatment, with about one-third of participants in both groups getting at least one dose, according to Regeneron.

Tags: Antibody Cocktailcovid treatmentsPfizerRegeneronvaccine
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Keshab Chandra Rout

December 12, 2019
#MyPaperBagChallenge

Akriti Negi

December 12, 2019
#MyPaperBagChallenge

Pratik Kumar

December 12, 2019
#MyPaperBagChallenge

Sipra Mishra

December 12, 2019
#MyPaperBagChallenge

Anshuman Sahoo

December 12, 2019
#MyPaperBagChallenge

Mandakini Dakua

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Sibarama Khotei

December 12, 2019
#MyPaperBagChallenge

Aishwarya Ranjan Mohanty

December 12, 2019
#MyPaperBagChallenge

Tapaswini Mallick

December 12, 2019
#MyPaperBagChallenge

Pratik Kumar Ghibela

December 12, 2019
#MyPaperBagChallenge

Sitakanta Mohanty

December 12, 2019
#MyPaperBagChallenge

Parbati Mohanty

December 12, 2019
#MyPaperBagChallenge

Adweeti Bhattacharya

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Spinoj Pattnaik

December 12, 2019
#MyPaperBagChallenge

Saishree Satyarupa

December 12, 2019
#MyPaperBagChallenge

Vandana Singh

December 12, 2019
#MyPaperBagChallenge

Anasuya Sahoo

December 12, 2019
#MyPaperBagChallenge

Sarfraz Ahmad

December 12, 2019
#MyPaperBagChallenge

Nishikant Rout

December 12, 2019
#MyPaperBagChallenge

Priyasha Pradhan

December 12, 2019
#MyPaperBagChallenge

Jhili Jena

December 12, 2019
#MyPaperBagChallenge

Manas Samanta

December 12, 2019
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
#MyPaperBagChallenge

Dibya Ranjan Das

December 12, 2019
#MyPaperBagChallenge

Smitarani Sahoo

December 12, 2019
#MyPaperBagChallenge

Pragyan Priyambada

December 12, 2019
#MyPaperBagChallenge

Lopali Pattnaik

December 12, 2019
#MyPaperBagChallenge

Jyotshna Mayee Pattnaik

December 12, 2019
#MyPaperBagChallenge

Chinmay Kumar Routray

December 12, 2019

Archives

Editorial

Covert Shame

Aakar Patel
November 22, 2026

By Aakar Patel Murders committed by the state in India have a name: encounter. Those who carry them out are...

Read moreDetails

An Emerging Norm

November 21, 2026

By Dilip Cherian Mallika Srinivasan’s third consecutive one-year extension as chairperson of the Public Enterprises Selection Board (PESB) is increasingly...

Read moreDetails

Tech Terror

November 18, 2026

It cannot be a coincidence that when the world was still trying to come to terms with the prospect of...

Read moreDetails

More Miseries Ahead

Inflation in India
November 17, 2026

Life is getting difficult by the day for Indians with all us citizens reeling under the dual shocks of rising...

Read moreDetails
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2025 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2025 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2025 All rights Reserved by OrissaPOST